Organization | Pharmacia & Upjohn

Pharmacia & Upjohn Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: London United Kingdom (1995)

Status: Acquired by Pharmacia (2000) → now Pfizer (2003)

Organization Overview

First Clinical Trial

1995

NCT01422317

First Marketed Drug

1995

heparin (liquaemin)

First NDA Approval

1995

ibutilide (corvert)

Last Known Activity

2006

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pharmacia and Upjohn | PHARMACIA AND UPJOHN | PHARMACIA UPJOHN

Active Ingredients

Marketed Drugs (68)

Key: Pharmacia & Upjohn (64) Acquired (4)

almotriptan (axert) (2001 NDA)

alprostadil (prostin) (1981)

arginine (1973 NDA)

bacitracin (polysporin) (1948)

benzodiazepine (1981)

benzphetamine (didrex) (1960)

cabergoline (dostinex) (1996 NDA)

calcium chloride (1991)

carboprost tromethamine (hemabate) (1979 NDA)

cefmetazole (zefazone) (1989 NDA)

cefpodoxime (vantin) (1992)

clindamycin (cleocin) (1980 NDA)

colestipol (colestid) (1977 NDA)

cortisone acetate (cortone) (1951)

cyclothiazide (anhydron) (1982)

dexrazoxane (zinecard) (1995)

diflorasone (FLORONE) (1977 NDA)

dinoprostone (prostin e2) (1977)

dinoprost tromethamine (prostin f2 alpha) (1975 NDA)

doxorubicin (Doxil) (1974)

estradiol (progynon depot) (1979)

estramustine (emcyt) (1981 NDA)

estropipate (ogen) (1977 NDA)

exemestane (aromasin) (1999 NDA)

fluorometholone (fml) (1977)

fluoxymesterone (1956)

fluprednisolone (alphadrol) (1978 NDA)

flurbiprofen (ansaid) (1988 NDA)

gentamicin (garamycin) (1980)

glucose monohydrate (1991)

glutathione (1991)

glyburide (micronase) (1984)

guanadrel (hylorel) (1982 NDA)

heparin (liquaemin) (1942)

hydrocortisone (solu-cortef) (1955)

ibutilide (corvert) (1995 NDA)

idarubicin (idamycin) (1990 NDA)

irinotecan (Camptosar) (1996 NDA)

latanoprost (xalatan) (1996 NDA)

lincomycin (lincocin) (1964 NDA)

linezolid (zyvox) (2000)

magnesium (1991)

medroxyprogesterone (provera) (1959 NDA)

methylprednisolone (medrol) (1957 NDA)

miglitol (glyset) (1996 NDA)

minoxidil (loniten) (1979)

naltrexone (revia) (1991)

neomycin (1964)

nicotine (nicorette) (1997)

novobiocin (albamycin) (1964)

pegvisomant (somavert) (2003 NDA)

potassium chloride (klor-con) (1991)

pramipexole (mirapex) (1997 NDA)

prednisone (meticorten) (1955)

rifabutin (mycobutin) (1992 NDA)

sodium bicarbonate (1991)

sodium chloride (1991)

sodium phosphate (1991)

somatropin (protropin) (1995)

sulfasalazine (azulfidine) (1950)

testosterone (delatestryl) (1979)

tetracycline (tetrex) (1954)

tolazamide (tolinase) (1966 NDA)

tolbutamide (orinase) (1957 NDA)

tolterodine (detrol) (1998 NDA)

tranexamic acid (cyklokapron) (1986 NDA)

triazolam (halcion) (1982 NDA)

urea (1952)

Drugs in Phase 4 Trials (2)

Key: Pharmacia & Upjohn (0) Acquired (2)

oxycodone (oxycontin) (1 trial)

pregabalin (lyrica) (1 trial)

Drugs in Phase 3 Trials (22)

Key: Pharmacia & Upjohn (10) Acquired (12)

carboplatin (paraplatin) (3 trials)

cisplatin (platinol) (1 trial)

corn (1 trial)

delavirdine (rescriptor) (9 trials)

didanosine (videx) (6 trials)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (2 trials)

icosapent ethyl (vascepa) (1 trial)

irinotecan (Camptosar) (8 trials)

lamivudine (epivir) (3 trials)

leflunomide (arava) (3 trials)

leucovorin (2 trials)

methylprednisolone (medrol) (1 trial)

mitoxantrone (novantrone) (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

paclitaxel (taxol) (1 trial)

prednisone (meticorten) (2 trials)

procarbazine (matulane) (1 trial)

romiplostim (nplate) (4 trials)

vitamin e (1 trial)

zidovudine (retrovir) (10 trials)

Drugs in Phase 2 Trials (12)

Key: Pharmacia & Upjohn (8) Acquired (4)

atevirdine (4 trials)

bevacizumab (avastin) (1 trial)

cytarabine (cytosar-u) (1 trial)

docetaxel (taxotere) (3 trials)

emivirine (1 trial)

epirubicin (ellence) (2 trials)

hydroxyurea (hydrea) (1 trial)

imatinib (gleevec) (1 trial)

mitomycin (mutamycin) (1 trial)

sargramostim (leukine) (1 trial)

stavudine (zerit) (2 trials)

zalcitabine (hivid) (2 trials)

Drugs in Phase 1 Trials (2)

Key: Pharmacia & Upjohn (1) Acquired (1)

alvircept sudotox (2 trials)

celecoxib (celebrex) (1 trial)

Drugs in Other Trials (4)

Key: Pharmacia & Upjohn (2) Acquired (2)

clindamycin (cleocin) (1 trial)

indinavir (crixivan) (3 trials)

nelfinavir (viracept) (1 trial)

pyrimethamine (daraprim) (1 trial)

Indications

Approved Indications

Adrenal Hyperplasia, Congenital

Amenorrhea

Arthritis, Rheumatoid

Asthma

Atrial Fibrillation

Bone Diseases, Infectious

Diabetes Mellitus, Type 2

Dwarfism, Pituitary

Dysmenorrhea

Empyema

Endometrial Hyperplasia

Endometritis

Genital Diseases, Female

Intraabdominal Infections

Leukemia, Myeloid, Acute

Lung Abscess

Lupus Erythematosus, Systemic

Menorrhagia

Migraine Disorders

Multiple Sclerosis

Mycobacterium avium-intracellulare Infection

Pneumococcal Infections

Pneumonia

Postpartum Hemorrhage

Pregnancy

Prolactinoma

Prostatic Neoplasms

Reproductive Tract Infections

Respiratory Tract Infections

Restless Legs Syndrome

Sepsis

Skin and Connective Tissue Diseases

Skin Diseases, Bacterial

Sleep Disorders, Intrinsic

Soft Tissue Infections

Staphylococcal Infections

Staphylococcal Skin Infections

Streptococcal Infections

Urinary Bladder, Overactive

Urinary Tract Infections

Uterine Hemorrhage

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 2)

Coronary Disease (Phase 3)

Esophageal Neoplasms (Phase 2)

HIV Infections (Phase 3)

Infarction (Phase 3)

Inflammatory Breast Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Myocardial Infarction (Phase 3)

Neoplasms, Unknown Primary (Phase 3)

Pancreatic Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 39
# of Trial APIs: 42